Patents by Inventor Michael A. Moskowitz
Michael A. Moskowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050106269Abstract: A method and compositions are provided for increased cerebral bioavailability of blood-born compositions by administering the composition of interest while increasing production of NO by eNOS, especially by administering L-arginine, by administering agents that increase NO levels independent of ecNOS, or by any combination of these methods. As NO is increased, cerebral blood flow is consequently increased, and drugs in the blood stream are carried along with the increased flow into brain tissue. By increased flow, the site of action will be exposed to more drug molecules. By stimulating increased NO production, administration of drugs that are not easily introduced to the brain may be facilitated and/or the serum concentration necessary to achieve desired physiologic effects may be reduced.Type: ApplicationFiled: September 28, 2004Publication date: May 19, 2005Applicant: eNOS PHARMACEUTICALS, INC.Inventors: Michael Moskowitz, James Liao, Eyal Ron, Mary Omstead
-
Publication number: 20050038102Abstract: A new use for HMG-CoA reductase inhibitors is provided. In the instant invention, HMG-CoA reductase inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity through a mechanism other than preventing the formation of oxidative-LDL. As a result, HMG-CoA reductase inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.Type: ApplicationFiled: October 15, 2003Publication date: February 17, 2005Applicants: BRIGHAM AND WOMENS HOSPITAL, The General Hospital CorporationInventors: James Liao, Ulrich Laufs, Matthias Endres, Michael Moskowitz
-
Patent number: 6818669Abstract: A method and compositions are provided for increased cerebral bioavailability of blood-born compositions by administering the composition of interest while increasing brain NO levels. This increase in NO levels may be accomplished by stimulating increased production of NO by eNOS, especially by administering L-arginine, by administering agents that increase NO levels independent of ecNOS, or by any combination of these methods. As NO is increased, cerebral blood flow is consequently increased, and drugs in the blood stream are carried along with the increased flow into brain tissue. By increased flow, the site of action will be exposed to more drug molecules. By stimulating increased NO production, administration of drugs that are not easily introduced to the brain may be facilitated and/or the serum concentration necessary to achieve desired physiologic effects may be reduced.Type: GrantFiled: September 19, 2001Date of Patent: November 16, 2004Assignee: Enos Pharmaceuticals, Inc.Inventors: Michael A. Moskowitz, James K. Liao, Eyal S. Ron, Mary Nallin Omstead
-
Publication number: 20040113945Abstract: A graphical user interface (“GUI”) and method is disclosed for use with a product specification computer program for specifying complex highly configurable products. The GUI provides for simultaneously displaying, navigating, selecting and assembling of complex objects/products and configuration thereof into a design layout using a multi-pane display. The display provides both two dimensional and three dimensional representations of the design layout as well as product selection and manipulation tools.Type: ApplicationFiled: December 12, 2002Publication date: June 17, 2004Applicant: Herman Miller, Inc.Inventors: Samuel H. Park, Keva Michael Moskowitz, Kevin Earl Meboe, Daniel Malcolm Toloudis
-
Patent number: 6630347Abstract: This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.Type: GrantFiled: October 20, 2000Date of Patent: October 7, 2003Assignee: The General Hospital CorporationInventors: Paul L. Huang, Mark C. Fishman, Michael A. Moskowitz
-
Publication number: 20030032616Abstract: A method and compositions are provided for increased cerebral bioavailability of blood-born compositions by administering the composition of interest while increasing brain NO levels. This increase in NO levels may be accomplished by stimulating increased production of NO by eNOS, especially by administering L-arginine, by administering agents that increase NO levels independent of ecNOS, or by any combination of these methods. As NO is increased, cerebral blood flow is consequently increased, and drugs in the blood stream are carried along with the increased flow into brain tissue. By increased flow, the site of action will be exposed to more drug molecules. By stimulating increased NO production, administration of drugs that are not easily introduced to the brain may be facilitated and/or the serum concentration necessary to achieve desired physiologic effects may be reduced.Type: ApplicationFiled: September 19, 2001Publication date: February 13, 2003Inventors: Michael A. Moskowitz, James K. Liao, Eyal S. Ron, Mary Nallin Omstead
-
Publication number: 20020077355Abstract: The invention relates to the use of epoxyeicosatrienoic acids and/or inducers of cytochrome P-450 epoxygenase activity to reduce brain injury in a subject with a cerebrovascular condition, including stroke.Type: ApplicationFiled: May 30, 2001Publication date: June 20, 2002Inventors: James K. Liao, Michael A. Moskowitz
-
Patent number: 6319955Abstract: The invention relates to the use of MEK1 inhibitors to reduce tissue damage resulting from ischemia and/or reperfusion, particularly brain damage associated with ischemia resulting from stroke. Pharmaceutical compositions, kits and perfusion fluids including MEK1 inhibitors are also provided.Type: GrantFiled: October 6, 2000Date of Patent: November 20, 2001Assignee: The General Hospital CorporationInventors: Alessandro Alessandrini, Joseph Bonventre, Michael A. Moskowitz, Shobu Namura
-
Publication number: 20010041688Abstract: Methods and compositions for the treatment of conditions which would benefit from vasoconstriction or the inhibition of vasoconstriction via modulation of sphingosine kinase and sphingosine-1-phosphate phosphatase activity and EDG receptor signaling are provided. These conditions include migraine, stroke, subarachnoid hemorrhage and vasospasm. Also provided are screening methods for modulators of sphingosine kinase and sphingosine-1-phosphate phosphatase activity and EDG receptor signaling which are capable of regulating vasoconstriction.Type: ApplicationFiled: March 13, 2001Publication date: November 15, 2001Inventors: Christian Waeber, Michael A. Moskowitz, Shin-Ichi Yoshimura, Salvatore Salomone
-
Patent number: 6310270Abstract: This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.Type: GrantFiled: March 14, 1997Date of Patent: October 30, 2001Assignee: The General Hospital CorporationInventors: Paul L. Huang, Mark C. Fishman, Michael A. Moskowitz
-
Patent number: 6150401Abstract: The invention relates to the use of MEK1 inhibitors to reduce tissue damage resulting from ischemia and/or reperfusion, particularly brain damage associated with ischemia resulting from stroke. Pharmaceutical compositions, kits and perfusion fluids including MEK1 inhibitors are also provided.Type: GrantFiled: January 6, 1999Date of Patent: November 21, 2000Assignee: The General Hospital CorporationInventors: Alessandro Alessandrini, Joseph Bonventre, Michael A. Moskowitz, Shobu Namura
-
Patent number: 6147109Abstract: A new use for HMG-CoA reductase inhibitors is provided. In the instant invention, HMG-CoA reductase inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity through a mechanism other than preventing the formation of oxidative-LDL. As a result, HMG-CoA reductase inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.Type: GrantFiled: August 11, 1998Date of Patent: November 14, 2000Assignees: The General Hospital Corporation, The Brigham and Women's Hospital Inc.Inventors: James K. Liao, Ulrich Laufs, Matthias Endres, Michael A. Moskowitz
-
Patent number: 5929061Abstract: The present invention provides methods for treating migraine headache comprising administering an effective amount of a neurosteroid that directly or indirectly activates GABA.sub.A receptors.Type: GrantFiled: January 26, 1998Date of Patent: July 27, 1999Assignee: The General Hospital CorporationInventor: Michael A. Moskowitz
-
Patent number: 5767117Abstract: The present invention provides methods for treating migraine headache. The methods useful according to the invention involve the treatment of patients who experience symptoms of migraine headache with compounds that directly or indirectly activate GABA.sub.A receptors.Type: GrantFiled: November 18, 1994Date of Patent: June 16, 1998Assignee: The General Hospital CorporationInventor: Michael A. Moskowitz
-
Patent number: 5733871Abstract: Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia, hypoxia, or neurodegeneration may result from stroke or cardiac arrest. This invention provides for the intravenous administration of neurotrophic factors such as bFGF, aFGF, NGF, CNTF, BDNF, NT3, NT4, IGF-I and IGF-II.Type: GrantFiled: March 16, 1995Date of Patent: March 31, 1998Assignee: The General Hospital CorporationInventors: Brian J. Alps, Christine Mary Brown, Franklin D. Collins, Caroline J. Emmett, Michael Spedding, Deborah Russell, Seth P. Finklestein, Michael A. Moskowitz, Roger Lewis Whiting
-
Patent number: 5409593Abstract: A device is provided for brush electroplating a surface of a workpiece. The device includes an anode generally composed of a metal to be electroplated on the surface of the workpiece. The anode is selectively retained within a cavity formed in a lower surface of a carrier piece composed of a generally electrical non-conductive material. The lower surface of the carrier piece is shaped to conform to at least a portion of the surface of the workpiece. An absorbent material extends over the lower surface of the carrier piece to form a brush. The cover material and lower surface of the anode are spaced from each other to form a chamber. The device also includes an assembly, fluidly connected to the space between the anode and absorbent material, to inject a flow of the electrolytic fluid into the chamber.Type: GrantFiled: December 3, 1993Date of Patent: April 25, 1995Assignee: Sifco Industries, Inc.Inventor: Michael Moskowitz
-
Patent number: 5385940Abstract: A method for treatment of stroke in a patient, involving administering to the patient a nitric oxide-releasing compound. A preferred compound of the invention is L-arginine.Type: GrantFiled: November 5, 1992Date of Patent: January 31, 1995Assignee: The General Hospital CorporationInventor: Michael A. Moskowitz